Welcome to our dedicated page for Intuitive Surgical news (Ticker: ISRG), a resource for investors and traders seeking the latest updates and insights on Intuitive Surgical stock.
Intuitive Surgical, Inc. (ISRG) is a medical technology company headquartered in Sunnyvale, California and known for its role in minimally invasive care and robotic-assisted surgery. Its news flow frequently centers on developments related to the da Vinci surgical systems and the Ion endoluminal system, along with financial performance updates and regulatory milestones.
Investors and healthcare professionals following ISRG news can expect regular earnings announcements, where the company reports quarterly and preliminary annual financial results. These updates typically highlight worldwide procedure growth on da Vinci and Ion platforms, changes in the installed base of systems, and trends in systems, instruments, and accessories revenue.
Another major category of Intuitive news involves product clearances and platform enhancements. Recent press releases describe FDA clearances expanding indications for the da Vinci Single Port (SP) system to additional general surgery procedures, clearance of advanced energy instruments such as Vessel Sealer Curved, and regulatory certifications for the da Vinci 5 system in regions including the European Union and Japan. News also covers software and digital features for da Vinci 5, such as Force Gauge, In-Console Video Replay, and Network CCM for remote software updates.
Intuitive’s news feed also includes updates on the Ion endoluminal system, including FDA-cleared software releases that introduce artificial intelligence across Ion’s navigational workflow and integrate advanced imaging capabilities to support lung biopsy procedures. Additional stories describe demonstrations of telesurgery capabilities using da Vinci 5 and collaborations with hospitals adopting newer platforms.
For those tracking ISRG, this news page provides a consolidated view of company press releases, allowing readers to monitor procedure and system trends, regulatory progress, and technology updates that shape Intuitive’s position in robotic-assisted surgery and minimally invasive care.
Intuitive Surgical's (NASDAQ:ISRG) da Vinci 5® robotic surgical system has been launched across all MemorialCare hospitals in Southern California, marking a significant expansion of advanced surgical capabilities. The system features 10,000 times more computing power than its predecessor and introduces over 150 design enhancements.
Key improvements include next-generation 3D imaging, Force Feedback technology that reduces tissue pressure by up to 43% in preclinical trials, and enhanced ergonomics. More than 120 surgeons across MemorialCare's three hospitals are trained to perform procedures in nine specialties using da Vinci platforms.
Intuitive (NASDAQ: ISRG) reported strong Q2 2025 financial results with revenue reaching $2.44 billion, up 21% year-over-year. The company's worldwide da Vinci procedures grew 17%, with 395 new system placements bringing the total installed base to 10,488 systems, a 14% increase from the previous year.
Key highlights include GAAP net income of $658 million ($1.81 per diluted share) and non-GAAP net income of $798 million ($2.19 per diluted share). The company secured important regulatory approvals, including European MDR certification and Japanese clearance for its da Vinci 5 surgical system.
For 2025, Intuitive projects worldwide da Vinci procedure growth of 15.5% to 17% and expects non-GAAP operating expense growth of 10% to 14%.
Intuitive (NASDAQ:ISRG), the robotic surgery pioneer, demonstrated groundbreaking telesurgery capabilities at the Society of Robotic Surgery conference in Strasbourg, France. Two surgeons, Dr. Doug Stoddard in Georgia and Dr. Andrea Pakula in France, successfully performed a transatlantic demonstration using a dual console da Vinci 5 system with Force Feedback technology.
The demonstration showcased remote surgical control capabilities across 4,000 miles, enabling surgeons to collaborate and share control of surgical instruments. CEO Dave Rosa emphasized that while telesurgery shows promise for improving patient access to minimally invasive care, the company prioritizes patient safety and practical value over technological advancement.
The demonstrated telesurgery software remains in development and is not yet FDA-cleared or CE marked. Intuitive has facilitated nearly 17 million da Vinci procedures and trained approximately 90,000 surgeons over its 30-year history.
Intuitive (Nasdaq: ISRG) has received FDA clearance for its new Vessel Sealer Curved, an advanced bipolar electrosurgical instrument designed for use with multiport da Vinci systems. The instrument represents a significant advancement in surgical technology, featuring a unique curved tip and fully wristed design for enhanced precision in minimally invasive procedures.
The device is FDA-cleared for sealing blood vessels up to 7mm in diameter and is notably the first of Intuitive's advanced energy instruments approved for lymphatic vessel transection. The curved jaw design follows natural anatomical contours, improving visibility and control in tight spaces. This milestone comes as Intuitive celebrates its 30th year in robotic-assisted technology, with nearly 17 million da Vinci procedures performed to date.
Intuitive (NASDAQ:ISRG) has received CE mark approval for its da Vinci 5 Surgical System in Europe, marking a significant milestone for the company's most advanced robotic-assisted surgical platform. The system is approved for both adult and pediatric use across abdominopelvic and thoracoscopic procedures.
The fifth-generation system features over 150 enhancements, including Force Feedback technology, an improved 3D vision system, and 10,000x more computing power. The platform has already received FDA clearance in 2024 for various procedures and joins Intuitive's portfolio of surgical systems that have been used in over 410,000 procedures in Europe in 2024 and nearly 17 million procedures worldwide.
Intuitive (NASDAQ: ISRG) announced a significant leadership transition, with President Dave Rosa being promoted to CEO effective July 1, 2025. Current CEO Gary Guthart will become executive chair of the board, while current Board Chair Craig Barratt will transition to lead independent director.
Rosa, a 29-year veteran who joined Intuitive as its ninth employee in 1996, has held various leadership positions across engineering, clinical development, marketing, and commercial operations. His notable achievements include founding the company's clinical engineering and endoluminal groups, leading to the development of the da Vinci SP surgical system and Ion robotic bronchoscopy system.
Under Guthart's 15-year tenure as CEO, Intuitive has pioneered advancements in robotic-assisted surgery, with surgeons performing nearly 17 million da Vinci procedures and training approximately 90,000 surgeons on their systems.
Intuitive (ISRG) reported strong Q1 2025 financial results with revenue reaching $2.25 billion, up 19% year-over-year. The company's da Vinci surgical system installations grew significantly, with 367 new placements (including 147 da Vinci 5 systems) compared to 313 in Q1 2024.
Key highlights include a 17% growth in worldwide da Vinci procedures and a 15% increase in the installed base to 10,189 systems. GAAP net income rose to $698 million ($1.92 per diluted share), while non-GAAP net income reached $662 million ($1.81 per diluted share).
The company ended Q1 with $9.10 billion in cash and investments. For 2025, Intuitive projects worldwide da Vinci procedure growth of 15-17% and expects non-GAAP operating expense growth of 10-14%.
Intuitive (NASDAQ: ISRG) announced two significant studies highlighting the impact of robotic-assisted surgery (RAS) on healthcare accessibility. The first study, published in the Journal of the Society of Laparoscopic & Robotic Surgeons, examined minimally invasive surgery (MIS) deserts and found that surgeon characteristics account for nearly two-thirds of variation in MIS use.
The second study, published in Annals of Surgery Open, analyzed data from 408 U.S. hospitals between 2016-2022. Hospitals implementing RAS saw MIS rates increase from 60.5% to 65.8%, compared to minimal growth (56.1% to 57.0%) in non-RAS hospitals. The greatest improvements were observed in hernia repairs and colorectal resections.
The research demonstrates that RAS helps overcome traditional laparoscopy barriers through shorter learning curves for surgeons and improved visualization, ultimately expanding patient access to minimally invasive procedures across various demographics.